Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2016 - 2025)

Rocket Pharmaceuticals' Total Current Liabilities history spans 10 years, with the latest figure at $30.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 25.75% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $30.2 million, down 25.75%, while the annual FY2025 figure was $30.2 million, 25.75% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $30.2 million at Rocket Pharmaceuticals, down from $31.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $48.5 million in Q4 2023 and bottomed at $22.2 million in Q4 2021.
  • The 5-year median for Total Current Liabilities is $33.2 million (2023), against an average of $33.4 million.
  • The largest annual shift saw Total Current Liabilities surged 91.78% in 2021 before it tumbled 44.26% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $22.2 million in 2021, then skyrocketed by 76.7% to $39.2 million in 2022, then rose by 23.84% to $48.5 million in 2023, then decreased by 16.12% to $40.7 million in 2024, then dropped by 25.75% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Total Current Liabilities are $30.2 million (Q4 2025), $31.2 million (Q3 2025), and $43.4 million (Q2 2025).